Clinical Trial Update: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating autologous anti-CD19 CAR-T cells given with a BTK inhibitor for B cell lymphomas, with an unspecified status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• autologous anti-CD19 CAR-T cells (CAR-T)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Status: UNKNOWN